dabrafenib,trametinib,pembrolizumab
merck,novartis
['melanoma', 'dabrafenib', 'keynote-022', 'trametinib', 'pembro']
today at #asco22: long-term follow-up of keynote-022 parts 1, 2, and 3! patients with braf(v600e/k)-mutant melanoma receiving 1l pembrolizumab + dabrafenib + trametinib continued to show improved pfs, dor, and os with no new safety signals identified 